Holzer & Holzer, LLC Reminds Shareholders of July 5, 2024 Lead Plaintiff Deadline in Altimmune, Inc. (ALT) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against Altimmune, Inc. alleging that the company made materially false and misleading statements regarding its business and prospects [1] - The lawsuit specifically claims that Altimmune overstated the potential of pemvidutide compared to competing GLP-1 agonists based on the results from the MOMENTUM Trial [1] - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than what was communicated to investors [1] - The lawsuit also contends that Altimmune's prospects for finding a strategic partner to develop pemvidutide were overstated as a result of these misleading statements [1] Legal Context - Investors who purchased Altimmune shares between December 1, 2023, and April 26, 2024, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is July 5, 2024 [3] - Holzer & Holzer, LLC is representing the shareholders and has a history of recovering significant amounts for investors affected by corporate misconduct [3]